Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

CRANFORD, N.J., Jan. 31, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that it will be presenting at the BIO CEO & Investor Conference. The conference will be held February 12-13, 2018 at the New York Marriott Marquis. The CTXR presentation will take place at 10:30 AM (Ziegfeld Room) on Tuesday, February 13, 2018.  Mr. Leonard Mazur, Executive Chairman of Citius, and Mr. Myron Holubiak, President and CEO, will be giving the presentation and meeting with investors during the conference.

Citius Pharmaceuticals presentation will provide an overview to the company's critical care drug products, as well as how they are advancing the drugs and will discuss milestone achievements. To arrange a meeting with management, please contact Mr. Andrew Scott: ascott@citiuspharma.com.

About Citius Pharmaceuticals, Inc.

Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously-approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs; by using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches. For more information, please visit www.citiuspharma.com.

Safe Harbor

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius.  You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. 

Contact:

Andrew Scott                                                              
Vice President, Corporate Development                                                       
908-967-6676
ascott@citiuspharma.com

 

Cision View original content:http://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-bio-ceo--investor-conference-300590465.html

SOURCE Citius Pharmaceuticals, Inc.